Oppenheimer & Co. Inc. Acquires 23,078 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Oppenheimer & Co. Inc. boosted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 28.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 104,487 shares of the biopharmaceutical company's stock after buying an additional 23,078 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.09% of Catalyst Pharmaceuticals worth $2,181,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Larson Financial Group LLC increased its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $65,000. KBC Group NV increased its stake in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after buying an additional 1,542 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $134,000. Finally, Quantbot Technologies LP purchased a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at $151,000. 79.22% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Steve Miller sold 50,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares of the company's stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

CPRX has been the topic of a number of analyst reports. Baird R W upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Robert W. Baird lifted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday. Truist Financial upped their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $32.50.

Catalyst Pharmaceuticals Stock Down 0.4 %

Shares of CPRX stock traded down $0.08 during mid-day trading on Thursday, reaching $21.81. 275,126 shares of the company's stock traded hands, compared to its average volume of 1,247,840. The company's 50-day moving average price is $22.27 and its 200-day moving average price is $21.49. The company has a market cap of $2.65 billion, a P/E ratio of 18.46, a P/E/G ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $24.64.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.